Stockholders’ Equity |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockholders’ Equity [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockholders’ Equity | Note 14 - Stockholders’ Equity
The total number of shares of capital stock that the Company has the authority to issue is up to 205,000,000 shares, consisting of: (i) 200,000,000 shares of common stock, having a par value of $0.001 per share; and (ii) 5,000,000 shares of preferred stock, having a par value of $0.001 per share, of which 1,000,000 shares have been designated as Series A Preferred Stock.
As of September 30, 2026, there were 6,006,678 shares of common stock and 256,125 shares of Series A Preferred Stock issued and outstanding. As of December 31, 2025, there were 5,269,799 shares of common stock and 250,000 shares of Series A Preferred Stock issued and outstanding.
The Series A Preferred Stock was excluded from diluted earnings per share for the three and nine months ended September 30, 2026, as the assumed conversion of such shares into common stock would have been anti-dilutive.
Stock Based Compensation
Equity Incentive Plan
We maintain the 2022 Plan, under which we may grant awards to employees, officers, directors, and certain other service providers. The compensation committee of the Board (the “Compensation Committee”) administers the 2022 Plan.
Pursuant to the evergreen provision of the 2022 Plan, the number of shares authorized for issuance under the 2022 Plan increases automatically on an annual basis. As a result of such increases, which commenced on October 15, 2025, the aggregate number of shares of common stock authorized for issuance under the 2022 Plan was 638,288 shares as of December 31, 2025.
There were no changes to the number of shares authorized for issuance under the 2022 Plan during the three and nine months ended September 30, 2026.
Ending balances for the 2022 Plan for the nine months ended September 30, 2026 are as follows:
Stock-based compensation expense for the three and nine months ended September 30, 2026, was $509,002 and $1,221,342 , respectively. Stock-based compensation expense for the three and nine months ended September 30, 2025 was $286,656 and $557,999, respectively.
Restricted Stock Units
The Company measures compensation cost for all stock-based awards granted to employees, directors, and certain other service providers based on the grant-date fair value of the award by ASC 718. The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the date of the grant.
During the nine months ended September 30, 2026, the Company granted 477,017 RSUs and forfeited 106,163 RSUs. The RSUs generally vest over periods ranging from to years from the respective grant dates, subject to continued service and other customary terms and conditions, in accordance with the applicable award agreements and the 2022 Plan.
A summary of RSU activity for the nine months ended September 30, 2026, is as follows:
As of September 30, 2026, 506,753 restricted stock units (“RSUs”) remained outstanding and unvested. RSUs had vested but remained unsettled through the issuance of common stock as of September 30, 2026. Accordingly, 506,753 RSUs remained outstanding as of September 30, 2026. The RSUs were excluded from diluted earnings per share for the three and nine months ended September 30, 2026, as their inclusion would have been anti-dilutive.
Short-Term Incentive Plan
On February 4, 2025, the Compensation Committee approved the Company’s 2025 Short-Term Incentive Plan, as amended and restated on April 23, 2026 (the “STIP”), providing for quarterly awards of performance-based RSUs under the 2022 Plan. The STIP is designed to reward executive officers and key employees based on the achievement of quarterly performance targets. The Compensation Committee has full power to administer and interpret the STIP and, in its sole discretion, may establish or amend the rules of general application for the administration of the STIP. For the three and nine months ended September 30, 2026, no quarterly awards were approved by the Compensation Committee under the STIP.
Warrants
During the years ended December 31, 2025 and 2024, the Company issued warrants to purchase shares of its common stock in connection with financing transactions, warrant inducement transactions, public offerings, registered direct offerings, and private placements. The warrants generally have fixed exercise prices, subject to adjustments set forth therein, are exercisable upon issuance or following stockholder approval, as applicable, and have contractual terms ranging from to years from their respective issuance dates.
All warrants issued by the Company remain classified as equity instruments and are recorded in additional paid-in capital. During the nine months ended September 30, 2026, there were no warrant issuances, exercises, modifications, repricing, or reclassifications. The proportional adjustment to the number of shares issuable upon exercise of the warrants resulting from the Reverse Stock Split was an anti-dilution adjustment under the applicable warrant terms and was not accounted for as a warrant modification or repricing.
As of September 30, 2026, the Company had 436,022 shares of common stock issuable upon exercise of outstanding warrants. The outstanding warrants were excluded from diluted earnings per share for the three and nine months ended September 30, 2026 and 2025, as their inclusion would have been anti-dilutive in accordance with ASC 260.
The following table presents the securities that were excluded from the computation of diluted net loss per share because their inclusion would have been anti-dilutive:
Shelf Registration Statement on Form S-3
On November 26, 2024, the Company’s shelf registration statement on Form S-3 (File No. 333-283284) (the “Form S-3”) was declared effective by the SEC. This registration statement permits the Company to offer and sell, from time to time, common stock, preferred stock, warrants, subscription rights, and units in one or more offerings, subject to market conditions and applicable regulatory requirements.
On December 19, 2024, the Company entered into an At the Market (“ATM”) Sales Agreement with A.G.P./Alliance Global Partners (“A.G.P.”) (the “A.G.P. Sales Agreement”), under which the Company was able to offer and sell shares of its common stock from time to time. The A.G.P. Sales Agreement was terminated effective March 29, 2025.
Following the termination of the ATM program with A.G.P. and the related A.G.P. Sales Agreement, the Company entered into an At-The-Market Offering Agreement (the “HCW Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), on April 2, 2025, under which the Company was able to offer and sell shares of its common stock having an aggregate offering price of up to $7,650,000.
On December 23, 2025, the Company filed a prospectus supplement to its Form S-3 to increase the aggregate offering price of shares of common stock available for issuance under the HCW Sales Agreement to up to $20,000,000. During the quarter ended March 31, 2026, the Company issued an aggregate 10,018 shares of common stock pursuant to its at-the-market (“ATM”) programs, with the last sale thereunder occurring on March 12, 2026, generating net proceeds of approximately $126,150 after deducting commissions and offering-related expenses of approximately $5,191. The amount and timing of future proceeds the Company may receive from the sale of shares of common stock pursuant to the HCW Sales Agreement, if any, will depend on a number of factors, including that the Company is eligible to use the Form S-3 to sell shares thereunder, the number of shares the Company may elect to sell, the timing of such sales and the future market price of the Company’s shares of common stock. As of the date of this Form 10-Q, the Company is unable to sell shares pursuant to the HCW Sales Agreement due to restrictions on the use of its Form S-3. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||